Navigation Links
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
Date:6/23/2009

HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen's 2009 International Expert Consensus on the primary therapy of early breast cancer. The recommendations have been published online in the Annals of Oncology and will appear in the August print edition.

The St. Gallen expert panel consists of key opinion leaders from across Europe (53%), the United States (33%), and rest of the world (14%). In the recently published article highlighting the 2009 recommendations, the panellists emphasize that "in an important change from the previous St. Gallen conference...the Panel supported the use of a validated multigene- profiling assay, if readily available, as an adjunct to high-quality phenotyping of breast cancer in cases in which the indication for adjuvant chemotherapy remained uncertain."

In addition, the panel cautioned that so-called intermediate scores are not useful in clinical decision making. Currently, MammaPrint is the only breast cancer recurrence assay available that accurately yields a binary result, without an intermediate group, addressing the panel's recommendations. The FDA-cleared assay is always clinically useful and indicates whether a patient is at low or high risk for metastasis and the resulting clarity is vital in helping physicians personalize treatment options.

"St. Gallen's guideline inclusion is a key step in further establishing MammaPrint as a standard of care. It also supports our commitment to upholding rigorous standards of quality and efficacy," said Dr. Bernhard Sixt, Agendia's President and Chief Executive Officer. "With MammaPrint we aim to provide breast cancer patients and their physicians with definitive answers to crucial treatment questions."

In addition to MammaPrint, the company also offers TargetPrint to further improve breast cancer treatment options. TargetPrint quantitatively determines the gene expression levels of HER2neu, estrogen and progesterone receptors. Ongoing research and development efforts continue to augment Agendia's ability to accurately predict breast cancer recurrence, and help physicians tailor individual treatment plans to their patients.

    For online access to the Annals of Oncology:
http://annonc.oxfordjournals.org/cgi/content/full/mdp322v1

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer therapy. The company markets four products, with several new genomic tests in development. Agendia collaborates with pharmaceutical companies in the development of highly effective personalized drugs in the area of oncology and was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
3. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
4. New Research Shows Antidepressants May Thwart Breast Cancer Treatment
5. Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
6. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
7. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
8. Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
11. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... MILWAUKEE (PRWEB) , ... March 19, 2020 , ... ... course is as safe and effective as single food immunotherapy, according to research ... (AAAAI) Annual Meeting before it was cancelled due to the situation with coronavirus ...
(Date:3/16/2020)... TAMPA, Fla. (PRWEB) , ... ... ... a unique, state-of-the-art, integrated, healthcare communication and patient education platform, with ... e-prescribe and track patient communication, dramatically improving how they support patients before, ...
(Date:3/16/2020)... ... March 16, 2020 , ... The Westat Board of Directors ... November 2017, is appointed President and Chief Executive Officer (CEO) effective March 16, 2020, ... the Board of Directors. , “Scott has brought strong leadership, management, and business development ...
Breaking Medicine Technology:
(Date:3/20/2020)... Quebec (PRWEB) , ... March 20, 2020 , ... ... to bring together an interdisciplinary team of researchers in machine learning, bioinformatics, immunology, ... deployed in current and future outbreaks. , "The COVID-19 crisis gives us an ...
(Date:3/19/2020)... ... , ... Sucheta Kamath, Founder and CEO of ExQ®, a ... Exercise: ExQ® Superpower Hour. During the recent closure of many schools ... the immediate need for activities that can be implemented at home, and the ...
(Date:3/19/2020)... ... March 20, 2020 , ... With ICH E8(R1) set to ... look different than they do today. Be ready to implement the new guidelines. ... shows readers how to leverage the revised guidelines’ quality-by-design approaches, expanded study designs and ...
(Date:3/15/2020)... ... March 13, 2020 , ... ... their mission to bridge the gap by connecting individuals with autism and other ... people to attain fulfilling and independent lives has not wavered. , These ...
(Date:3/13/2020)... ... March 13, 2020 , ... The Berman Law Group today announced that it ... Province, the City of Wuhan, and several Chinese government ministries, on behalf of residents ... filed in the Southern District of Florida, and seeks billions of dollars in compensatory ...
Breaking Medicine News(10 mins):